ACT was effective against JAK2 loss tumors, but not JAK1 loss tumors in an IFN signaling-deficient model of B16 murine melanoma, and overexpression of NLRC5(nucleotide-binding oligomerization domain-like receptor family caspase recruitment domain containing 5) restored the efficacy of ACT against B16-JAK1 loss tumors [112]. This evidence concerns the gene JAK2 and melanoma.